takeoff.watch

A brain implant is approved for healthy people

Will the FDA, or the medical-device regulator of any other G20 country, approve an implanted brain–computer interface for use in people with no medical condition?

Chance by Q4 2031

1%

Cumulative probability

0%25%50%75%100%
  • Latest forecast

Forecast history

Forecast made on 12 Oct 2026

Latest of 4 forecasts · Methodology v2.1

Model reasoning

Forecast made 12 Oct 2026 · Methodology v2.1

No regulator anywhere has approved a brain implant for healthy people. Only China, in March 2026, has approved any brain implant for sale, and only for paralysed patients. Approving one for healthy users would first require trials in healthy volunteers, which have not started anywhere, and even Neuralink only hopes to implant a healthy person by 2030. What would most change this is a major regulator approving a trial of brain implants in healthy volunteers.

Where things stand (as of 2026-10-12)

No regulator anywhere has authorized an implanted brain–computer interface for healthy users, and none is close. One implanted BCI has a market approval anywhere in the world: China's NMPA registered Neuracle's epidural "NEO" system as a Class III device on 13 March 2026. Its indication is narrow and therapeutic: adults aged 18–60 with C2–C6 cervical spinal cord injury who cannot grasp. Within 11 days it had an insurance code and procurement listing, and the first commercial implant was in July 2026. The other Chinese neuro-device approvals (closed-loop deep brain stimulation for Parkinson's, deep brain stimulation for addiction) are also for medical conditions.

In the US, no implanted BCI has a premarket approval yet. Neuralink's own trials page still says its devices are investigational. It has about 26 participants, all with paralysis or ALS. Synchron is only now preparing its first pivotal trial, and Paradromics' recent "FDA approval" was an expansion of its investigational study. Roughly 150 people worldwide have ever had BCI electrodes implanted. As far as I could find, no healthy-volunteer trial of an implanted BCI has started in any country.

What the developers and governments say:

  • Neuralink says it "hopes to put its device in a healthy person by 2030." That is a first implant, presumably in a trial, not an approval.
  • Neuralink president DJ Seo (May 2026, known to me only from a search snippet of a Dealroom note) described off-label use after a therapeutic approval as the route for healthy people. Off-label use is explicitly excluded by this question.
  • China's 2024 national ethics guidance on BCI research says enhancement BCIs are "generally non-invasive," that research should mainly target restoring lost function, and that enhancement applications should not be rushed.
  • China's 2025 seven-ministry implementation plan treats implanted BCIs as medical devices and assigns consumer and everyday uses to non-implanted products.
  • Chinese experts quoted by Xinhua (January 2026) describe invasive BCIs as a high-barrier medical technology for seriously ill patients.

Reference class and base rate

Regulators do approve implants for healthy people: breast implants and dermal fillers are approved for cosmetic use. But no neural implant has ever received a non-medical or enhancement indication. Deep brain stimulation (US approval 1997) and cochlear implants (1984) have been on the market for decades without one. So the base rate for an enhancement indication on any neural implant is essentially zero.

A healthy-user approval would need, in order:

  1. regulators and ethics boards allowing brain surgery on healthy volunteers;
  2. a trial in healthy people with long-term follow-up (typically one to two years for implants);
  3. a review of 6 to 12 months or more.

Even taking Neuralink's own 2030 target as the start of step 1, approval would land after 2031.

Paths to YES

  • US: a deregulatory FDA, Neuralink's political influence (it hired a senior official from the FDA office that regulates it), and US–China rivalry produce an unusually fast healthy-user indication, perhaps by extrapolating safety data from patients. About 0.3–0.4% by 2031.
  • China: the state decides to promote implanted enhancement, reversing its own ethics guidance. China's speed with NEO shows it can move fast once it chooses to. About 0.3–0.4%.
  • Another G20 regulator: for example Argentina or Saudi Arabia, trying to attract investment. These regulators mostly rely on reference-country approvals, so about 0.2%.
  • Edge case: an approval whose wording is read as qualifying. About 0.1–0.2%.

Forecast shape

I set quarterly hazards rather than writing cumulative numbers by hand: 0.02% per quarter through 2027, then 0.03% (2028), 0.05% (2029), 0.08% (2030) and 0.12% (2031). The rise tracks the earliest plausible order of therapeutic approvals followed by healthy-volunteer trials. I accumulated them as 1 − ∏(1 − h) in Python. The cumulative probability is about 0.1% at end-2027, 0.4% at end-2029 and 1.2% at end-2031.

Strongest case against my estimate

The field is moving fast. China went from first implant to commercial approval in about 2.5 years, investment is booming, and AI-driven acceleration could compress timelines. Several founders (Musk; Altman's Merge Labs) are openly aiming at healthy users. Five years is long in this sector. This is why I don't go below about 1%. But every published plan still puts healthy-user implantation itself around 2030, which leaves too little time for evidence and review by the end of 2031.

Sources

Resolution criteria

Opened 16 Sep 2026Not yet resolved

Question. By the last day of each quarter, has the FDA, or the medical-device regulator of any other G20 country, approved an implanted brain–computer interface for use in people with no medical condition?

Definitions.

  • G20 country: one of the 19 sovereign-country members at opening: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, South Africa, South Korea, Türkiye, the United Kingdom, or the United States. Membership in the European Union or African Union alone does not qualify a country.
  • Implanted brain–computer interface (BCI): a system with a surgically implanted component that reads brain activity and translates it into computer or device inputs, or conveys computer-generated information directly to the brain through neural stimulation. Intracortical, cortical-surface, epidural, and endovascular interfaces count; the entire system need not be implanted. Peripheral-nerve-only interfaces, muscle-signal interfaces, passive identification chips, and external-only headsets do not count. Stimulation solely to modulate a physiological state, without transmitting information or enabling communication or control, does not count.
  • Approve: issue a final regulatory authorization permitting supply and implantation for the specified use outside a clinical investigation. Marketing approval, clearance, device registration, and a formally approved expansion of intended use count regardless of the pathway's name. Conditional authorization counts if it permits non-investigational use; a decision authorizing only research does not.
  • People with no medical condition: the authorized intended population explicitly includes healthy people, and the authorized use does not require a disease, injury, disability, diagnosed disorder, or other medical condition. Elective enhancement, communication, entertainment, or device control in healthy users qualifies. The authorization need not exclude people with incidental conditions. A therapeutic authorization with no explicit healthy-user indication does not qualify merely because its contraindications fail to forbid healthy users.

Resolves YES if an eligible regulator publishes an approval decision, authorized labeling, device-register entry, or official announcement establishing both a qualifying authorization and its healthy-user indication. No actual implantation, sale, reimbursement, or AI component is required. A new healthy-user indication for a previously approved therapeutic BCI counts.

Resolves NO / Exclusions.

  • No qualifying public authorization by the quarter-end.
  • Investigational Device Exemptions, clinical-trial permissions (including trials in healthy volunteers), ethics approvals, compassionate-use permissions, breakthrough designations, submissions, and announced intentions to approve.
  • Off-label implantation in healthy people, regulatory silence or non-enforcement, or permission to sell an unregulated consumer product without an affirmative device authorization.
  • Approval only for patients with a condition, including paralysis, amputation, depression, or sensory impairment. Approval of a component alone does not count unless its authorized use establishes the qualifying implanted BCI use in healthy people.
  • A manufacturer declaration or European notified-body certificate alone is insufficient: for France, Germany, or Italy, an official national medical-device competent-authority publication must affirm that the specified healthy-user use is authorized in that country.

Resolving source. Official records of the FDA; Argentina's ANMAT; Australia's TGA; Brazil's ANVISA; Health Canada; China's NMPA; France's ANSM; Germany's BfArM or competent state medical-device authority; Italy's Ministry of Health; India's CDSCO; Indonesia's Ministry of Health; Japan's MHLW/PMDA; Mexico's COFEPRIS; Russia's Roszdravnadzor; the Saudi Food and Drug Authority; South Africa's SAHPRA; South Korea's MFDS; Türkiye's TİTCK; or the United Kingdom's MHRA, including successor bodies legally exercising the same function. Use the regulator's decision and authorized intended-use text, not manufacturer or press descriptions of an “approval.” This is a narrower source requirement than Public confirmation (A2). Apply Resolution date (A3) and the Resolution window; only qualifying publications from 2026-09-16 onward count. The FDA's May 2021 Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation — Non-clinical Testing and Clinical Considerations is guidance for investigations, not a qualifying product approval.

Download all forecasts (JSON)